These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21450365)

  • 1. Risk factors and clinical significance of ertapenem-resistant Klebsiella pneumoniae in hospitalised patients.
    Orsi GB; García-Fernández A; Giordano A; Venditti C; Bencardino A; Gianfreda R; Falcone M; Carattoli A; Venditti M
    J Hosp Infect; 2011 May; 78(1):54-8. PubMed ID: 21450365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case-control study.
    Orsi GB; Bencardino A; Vena A; Carattoli A; Venditti C; Falcone M; Giordano A; Venditti M
    Infection; 2013 Feb; 41(1):61-7. PubMed ID: 23070604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study.
    Liu SW; Chang HJ; Chia JH; Kuo AJ; Wu TL; Lee MH
    J Microbiol Immunol Infect; 2012 Apr; 45(2):113-9. PubMed ID: 22154994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of carbapenem resistance among plasmid-mediated AmpC β-lactamase-producing Klebsiella pneumoniae during outbreaks in liver transplantation units.
    Matsumura Y; Tanaka M; Yamamoto M; Nagao M; Machida K; Ito Y; Takakura S; Ogawa K; Yoshizawa A; Fujimoto Y; Okamoto S; Uemoto S; Ichiyama S
    Int J Antimicrob Agents; 2015 Jan; 45(1):33-40. PubMed ID: 25455850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.
    Lee CH; Chu C; Liu JW; Chen YS; Chiu CJ; Su LH
    J Antimicrob Chemother; 2007 Aug; 60(2):410-3. PubMed ID: 17576696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan.
    Nadkarni AS; Schliep T; Khan L; Zeana CB
    Am J Infect Control; 2009 Mar; 37(2):121-6. PubMed ID: 19249638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.
    Zarkotou O; Pournaras S; Tselioti P; Dragoumanos V; Pitiriga V; Ranellou K; Prekates A; Themeli-Digalaki K; Tsakris A
    Clin Microbiol Infect; 2011 Dec; 17(12):1798-803. PubMed ID: 21595793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.
    Mosqueda-Gómez JL; Montaño-Loza A; Rolón AL; Cervantes C; Bobadilla-del-Valle JM; Silva-Sánchez J; Garza-Ramos U; Villasís-Keever A; Galindo-Fraga A; Palacios GM; Ponce-de-León A; Sifuentes-Osornio J
    Int J Infect Dis; 2008 Nov; 12(6):653-9. PubMed ID: 18511321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outbreak caused by an ertapenem-resistant, CTX-M-15-producing Klebsiella pneumoniae sequence type 101 clone carrying an OmpK36 porin variant.
    Poulou A; Voulgari E; Vrioni G; Koumaki V; Xidopoulos G; Chatzipantazi V; Markou F; Tsakris A
    J Clin Microbiol; 2013 Oct; 51(10):3176-82. PubMed ID: 23850951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of an outbreak of antibiotic-resistant Klebsiella pneumoniae at a tertiary care medical center.
    Filozov A; Visintainer P; Carbonaro C; Aguero-Rosenfeld M; Wormser GP; Montecalvo MA
    Am J Infect Control; 2009 Nov; 37(9):723-8. PubMed ID: 19501935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.
    Lee CH; Su LH; Tang YF; Liu JW
    J Antimicrob Chemother; 2006 Nov; 58(5):1074-7. PubMed ID: 16971415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy.
    Findlay J; Hamouda A; Dancer SJ; Amyes SG
    Clin Microbiol Infect; 2012 Feb; 18(2):140-6. PubMed ID: 21745255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo selection of OmpK35-deficient mutant after cefuroxime therapy for primary liver abscess caused by Klebsiella pneumoniae.
    Lee CH; Chia JH; Chu C; Wu TL; Liu JW; Su LH
    J Antimicrob Chemother; 2006 Oct; 58(4):857-60. PubMed ID: 16880175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase.
    Peña C; Pujol M; Ardanuy C; Ricart A; Pallarés R; Liñares J; Ariza J; Gudiol F
    J Hosp Infect; 2001 Jan; 47(1):53-9. PubMed ID: 11161899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
    Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
    J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of molecular characteristics, risk factors, and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
    Cheng Y; Cheng Q; Zhang R; Gao JY; Li W; Wang FK; He ZX; Sun QQ; Meng HB; Yu S
    BMC Microbiol; 2024 Aug; 24(1):309. PubMed ID: 39174950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors, outcomes and genotypes of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infection: a three-year retrospective study in a large tertiary hospital in Northern China.
    Zheng SH; Cao SJ; Xu H; Feng D; Wan LP; Wang GJ; Xiao XG
    Infect Dis (Lond); 2018 Jun; 50(6):443-451. PubMed ID: 29303020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece.
    Pournaras S; Protonotariou E; Voulgari E; Kristo I; Dimitroulia E; Vitti D; Tsalidou M; Maniatis AN; Tsakris A; Sofianou D
    J Antimicrob Chemother; 2009 Aug; 64(2):348-52. PubMed ID: 19525514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-{beta}-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study.
    Kritsotakis EI; Tsioutis C; Roumbelaki M; Christidou A; Gikas A
    J Antimicrob Chemother; 2011 Jun; 66(6):1383-91. PubMed ID: 21454344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study.
    Giannella M; Trecarichi EM; De Rosa FG; Del Bono V; Bassetti M; Lewis RE; Losito AR; Corcione S; Saffioti C; Bartoletti M; Maiuro G; Cardellino CS; Tedeschi S; Cauda R; Viscoli C; Viale P; Tumbarello M
    Clin Microbiol Infect; 2014 Dec; 20(12):1357-62. PubMed ID: 24980276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.